Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143877 | 0.87 | CYP3A4 (0.57) | NR1H4MAPTKMT2ACA1CA2 | |
| SCHEMBL2330778 | 0.87 | MAPT (0.55) | NR1H4MAPTKMT2AHIF1ACA1 | |
| SCHEMBL8862701 | 0.85 | NR1H4 (0.58) | NR1H4MAPTHSD17B10KMT2ACA1 | |
| SCHEMBL8429886 | 0.85 | MAPT (0.60) | MAPTHSD17B10KMT2AHIF1ACA1 | |
| SCHEMBL2252810 | 0.83 | MAPT (0.58) | MAPTHSD17B10KMT2AHIF1ACA1 | |
| SCHEMBL2985242 | 0.82 | MAPT (0.57) | MAPTHSD17B10KMT2AHIF1ACA1 | |
| SCHEMBL1252482 | 0.82 | MAPT (0.57) | MAPTHSD17B10KMT2ACA1CA2 | |
| SCHEMBL184552 | 0.82 | MAPT (0.57) | MAPTKMT2AHIF1ACA1CA2 | |
| SCHEMBL8529739 | 0.82 | MAPT (0.57) | MAPTHSD17B10KMT2AHIF1ACA1 | |
| SCHEMBL13306149 | 0.82 | MAPT (0.57) | MAPTHSD17B10KMT2AHIF1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717706-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC | 2015-12-10 | — | — | US | disclosed |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2533637-B1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8669381-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8481590-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2533637-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011099978-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| US-RE37035-E1 | HYPOGLYCEMIC AGENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-01-30 | — | — | US | disclosed |
| US-6143769-A | ENANTIOMORPH | KARL THOMAE GMBH (DE) | 2000-11-07 | — | — | US | disclosed |
| US-5399702-A | Leukotriene antagonists; antiasthmatic, antiallergen, and antianaphylactic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5312924-A | Compounds for lowering blood sugar and effecting metabolism | DR. KARL THOMAE GMBH (DE) | 1994-05-17 | — | — | US | disclosed |
| EP-0577003-A1 | Thiazolylvinylphenyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-01-05 | — | — | EP | disclosed |
| US-5273986-A | A substituted phenylalkyleneamidophenyleneethylene thiazole | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5216167-A | Hypoglycemic agents | DR. KARL THOMAE GMBH (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0147850-A2 | Phenylacetic-acid derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | NR1H4 981/4885MAPT 3897/4885HSD17B10 50/4885 |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | NR1H4 981/4885MAPT 3897/4885HSD17B10 50/4885 |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | NR1H4 981/4885MAPT 3897/4885HSD17B10 50/4885 |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | NR1H4 981/4885MAPT 3897/4885HSD17B10 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.